Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.

as seen in the chart below. The stock is currently trading below both its 50 and 200-day moving averages. The dive in Novo Nordisk's stock price in March 2025 was primarily due to a pipeline setback.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...